Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 641-645, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elferink, F.
Right arrow Articles by Pinedo, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elferink, F.
Right arrow Articles by Pinedo, H. M.

Clinical Chemistry, Vol 32, 641-645, Copyright © 1986 by American Association for Clinical Chemistry

Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding

F Elferink, WJ van der Vijgh, I Klein and HM Pinedo

Toxicity of cisplatin can be decreased by concomitant administration of sodium thiosulfate, which perhaps chemically inactivates this platinum compound. We studied the disappearance of cisplatin and carboplatin in aqueous solutions of thiosulfate at 37 degrees C by means of liquid chromatography. At initial concentrations that were similar to therapeutic concentrations in plasma, both drugs disappeared, with half- lives of 66 and 537 min for cisplatin and carboplatin, respectively. At higher thiosulfate concentrations, as found in urine, the respective half-lives were 3.7 and 33.8 min. These values suggest that direct chemical interaction in the plasma compartment has limited therapeutic consequences, whereas the anti-toxic effect of thiosulfate might be explained by the rapid inactivation of cisplatin in the kidneys. Reaction products of cisplatin and thiosulfate bound instantaneously and mainly reversibly to plasma proteins. Protein-bound cisplatin was not released by added thiosulfate--which may explain why thiosulfate, to be effective, must be given in advance of and during cisplatin administration.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, and C. P. Reynolds
Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity
Clin. Cancer Res., January 15, 2008; 14(2): 533 - 540.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
P. Videhult, G. Laurell, I. Wallin, and H. Ehrsson
Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration.
Experimental Biology and Medicine, November 1, 2006; 231(10): 1638 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. W.T. Alkureishi, R. de Bree, and G. L. Ross
RADPLAT: An Alternative to Surgery?
Oncologist, May 1, 2006; 11(5): 469 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. D. Doolittle, L. L. Muldoon, R. E. Brummett, R. M. Tyson, C. Lacy, J. S. Bubalo, D. F. Kraemer, M. C. Heinrich, J. A. Henry, and E. A. Neuwelt
Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors
Clin. Cancer Res., March 1, 2001; 7(3): 493 - 500.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
L. L. Muldoon, M. A. Pagel, R. A. Kroll, R. E. Brummett, N. D. Doolittle, E. G. Zuhowski, M. J. Egorin, and E. A. Neuwelt
Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity
Clin. Cancer Res., January 1, 2000; 6(1): 309 - 315.
[Abstract] [Full Text]

Home page
 Am. J. Neuroradiol.Home page
D. Fortin, L. D. McAllister, G. Nesbit, N. D. Doolittle, M. Miner, E. J. Hanson, and E. A. Neuwelt
Unusual Cervical Spinal Cord Toxicity Associated with Intra-arterial Carboplatin, Intra-arterial or Intravenous Etoposide Phosphate, and Intravenous Cyclophosphamide in Conjunction with Osmotic Blood Brain-Barrier Disruption in the Vertebral Artery
AJNR Am. J. Neuroradiol., November 1, 1999; 20(10): 1794 - 1802.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. A. Neuwelt, R. E. Brummett, N. D. Doolittle, L. L. Muldoon, R. A. Kroll, M. A. Pagel, R. Dojan, V. Church, L. G. Remsen, and J. S. Bubalo
First Evidence of Otoprotection Against Carboplatin-Induced Hearing Loss with a Two-Compartment System in Patients with Central Nervous System Malignancy Using Sodium Thiosulfate
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 77 - 84.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
A. I. Ivanov, J. Christodoulou, J. A. Parkinson, K. J. Barnham, A. Tucker, J. Woodrow, and P. J. Sadler
Cisplatin Binding Sites on Human Albumin
J. Biol. Chem., June 12, 1998; 273(24): 14721 - 14730.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.